论文部分内容阅读
目的:探讨复方苦参注射液联合盐酸羟考酮缓释片对中重度癌痛患者的临床疗效。方法:将78例经NRS评分为中重度疼痛的肿瘤患者随机分为对照组(39例)和观察组(39例),对照组给予单纯口服盐酸羟考酮缓释片,观察组给予复方苦参注射液联合盐酸羟考酮缓释片,观察两组癌痛患者治疗前后NRS评分变化情况及不良反应的发生,评估疼痛缓解程度,从而评价复方苦参注射液在肿瘤癌痛患者治疗中的临床疗效及应用安全性。结果:实验结果显示,观察组有效率明显高于对照组,且观察组每人每日羟考酮用量及每人一周用量均少于对照组;两组患者治疗过程中均未出现明显心、肝、肾功能异常,两组不良反应发生率无统计学差异。结论:复方苦参注射液联合盐酸羟考酮缓释片对癌痛患者的临床疗效优于单纯口服盐酸羟考酮缓释片,且临床应用安全性较好。
Objective: To investigate the clinical efficacy of Compound Kushen Injection combined with oxycodone hydrochloride sustained-release tablets in patients with moderate-severe cancer. Methods: Totally 78 patients with moderate-severe pain were divided into control group (39 cases) and observation group (39 cases). The control group was given oral oxycodone hydrochloride sustained-release tablets. The observation group was given compound Ginseng injection combined with oxycodone hydrochloride sustained-release tablets to observe the two groups of patients with cancer pain before and after treatment NRS score changes and adverse reactions occurred to assess the degree of pain relief to evaluate the compound Kushen injection in the treatment of cancer patients with cancer pain Clinical efficacy and application safety. Results: The experimental results showed that the effective rate of the observation group was significantly higher than that of the control group, and the daily consumption of oxycodone and the weekly dosage of one week in the observation group were less than those in the control group. No significant cardiac, Liver and kidney dysfunction, the incidence of adverse reactions was no significant difference between the two groups. Conclusion: Compound Kushen injection combined with oxycodone hydrochloride sustained-release tablets in patients with cancer pain is better than the simple oral oxycodone hydrochloride oral sustained-release tablets, and the safety of clinical application is good.